NeoGenomics (NEO) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
October 29, 2015 7:02 AM EDTFT. MYERS, Fla., Oct. 29, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2015.
Third Quarter 2015 Highlights:
25% growth in base(1) test volume 8% growth in consolidated revenue despite $1.9 million reduction in FISH reimbursement 12.5% reduction in Avg. Cost per Test in base(1) business Adjusted EBITDA(2) increase to a record high $2.8 million and EPS of ($.00) per shareConsolidated Revenue for the third... More
NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services
October 28, 2015 7:08 PM EDTFT. MYERS, Fla., Oct. 28, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an amended Strategic Alliance Agreement with Covance Central Laboratory Services.Â
The Strategic Alliance Agreement, originally executed on Nov. 18, 2013, established NeoGenomics and Covance as mutually exclusive partners for the provision of NeoGenomics' specialty laboratory services, including certain anatomic pathology and histology testing, for Covance's central laboratory customers. The amendment, which reflects the February 2015 merger of Covance and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), will... More
